Evidence points to the origins of COVID-19 variants; officials urge former President Trump to encourage supporters to receive a COVID-19 vaccine; Purdue Pharma releases a bankruptcy plan.
Evidence suggests variants of COVID-19 likely evolved inside individuals with weak immune systems, such as those with cancer or other conditions, The New York Times reports. Scientists believe that as the virus infects someone with a weak immune system, the host allows it to adapt and evolve for months before being transmitted to others. In most people, an infection only lasts about a week, which is not long enough for the virus to acquire more than 1 mutation, if any. The evidence underscores the need to vaccinate those with compromised immune systems as soon as possible to lower the risk their bodies turn into incubators for the next mutant virus, experts said.
Former coronavirus testing czar, Adm. Brett Giroir, urged former President Donald Trump to encourage his supporters to get vaccinated against COVID-19, The Hill reports. Giroir also noted former Vice President Mike Pence ought to do the same. Currently, Republican men remain one of the key groups refusing to get vaccinated, as a recent poll found 49% said they would not get a COVID-19 vaccine. Among those who supported President Trump in the 2020 election, 47% said they would not be vaccinated if they had the opportunity. In comparison, 6% of democratic men and 10% of those who supported President Biden reported the same.
Monday night, Purdue Pharma reported a bankruptcy plan under which it would pay approximately $500 million in cash up front to settle the hundreds of thousands of injury claims linked to its role in the opioid epidemic, according to NPR. Over the next decade, additional payments would be made, including installments of close to $4.2 billion promised by members of the Sackler family, and the company predicts as much as $1 billion in additional payments would occur by 2024. However, the plan was immediately rejected by 24 state attorneys general who demanded more money should be paid up front to help communities provide treatment and public health services.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen